Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CA4P combined with paclitaxel and carboplatin for advanced head and neck solid tumors
ChiCTR-ONC-13003700Phase 2Completed
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Oct 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fosbretabulin, paclitaxel and carboplatin in head and neck cancer (HNC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: RECIST tumor response and CT or MRI assessment. Started Oct 2013; status: completed.
02
Drugs
fosbretabulinpaclitaxelcarboplatin
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on ChiCTR-ONC-13003700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-13003700.